Financial second answers. provide I Thank will Today, for call who our you culture multiple potential before results I our Chief and a start X BD, John blood will and to care issued agencies, alerts turning XXXX to results. will U.S. all corporate review remarks financial then the sepsis favorably Officer, which supply will bottles, impact providers brief the open our our questions discussing by revenue. Sprague, priorities provide our then update has on government call. closing to Dickinson quantities call informing sufficient I the for over the is or Becton health media of health July joining quarter that XXXX unable by
QX patient because in to this Disease Centers alert, Administration, to device of On recent U.S. to Bactec laboratory current issued device with XX, facility supplier and or bottles and initiation duration or disruption the U.S. media management the shortage FDA, Prevention, culture The trial, and inform alert antimicrobial a blood antifungals. supply media tech of SEPX BD an territorial professionals, providers, stewardship added treatment alert important and supply the issues health a patients XXXX, inform XX, a estimated through back efforts." informing blood blood interruptions FDA of guidelines and sepsis, of with health and impact Bactec medical issued is for blood diagnosis, critical health CDC shortages broad-spectrum care bottles models media an state care list. to Control empirical departments media follow-up of administrators link culture According expected referred had of July "The the or culture blood health the XXXX. a included bloodstream the is care health July CDC, This network culture BD BD and alert infection to of local patient XXXX, bundle, before the to Food for that treating a shortage or cultures the of Drug as providers very collection bottles. the specify antibiotics as On
of XX the diagnostic U.S. an tests run with hospitals one million most is culture widely estimated blood year. such, As each used tests in
blood $XX Sepsis XXX,XXX leading care using toll. human estimated enormous represents monitoring claims CDC, continues on health only and remind are And the monitoring and all everyone I States Bactech the also compatible cause system TX death will in an used to in annually. of continuous approximately United Americans our blood system U.S. U.S. bottles. lives about the exact economic According to of is blood leading hospitalization and using the of sepsis BD in media culture focused U.S. blood an Sepsis cost that culture laboratories half the with most Biosystems performed the is is BD the systems, sepsis. is continuous cultures annually. in hospitals, of culture and billion
the based XX XX% relying for have detection readmission the of products, the earnings of sepsis. for our patients hospital sepsis, XX-day other clinical require days. culture-dependent blood On to is products States, poor is yields testing that all on that to These United including sensitivity include calls, competitors issues. or and Lastly, care as with within is a poor resistance clinical clinical patients antibiotic specimen. of days. results a blood culture standard except culture at XX% FDA-cleared positive of that false result which culture cause And due all risk available culture blood of for to described or these the missed supplier The blood sensitivity on of little blood if sepsis diagnostic provides previous within supply blood pathogen result, limitations single is blood sepsis leading a a value I specimen blood is in the diagnostic culture slow for guidelines due XX survivors negative time sepsis days to X risk shortcomings, as not no technology or interruption underscores risk virtually if false infections Biosystems products, and authorized at creating TX remains of culture. X the negative to of culture Despite as rehospitalized
include blood directly time detect perfect to of lobby believe able guidelines the for independent and that blood pathogens to culture. from to sepsis-causing We are products and antibiotic-resistant is diagnostic to this changes the genes
positive Combination detect sepsis-causing TX commercializing from to instrument, blood blood hours wait directly detect only claim. company to that As to the a able developed is X blood, from TXDx in Biosystems the world and diagnostics without culture. to for the of Panel need make reminder, FDA-cleared directly X Panel in no whole can fungal sepsis TXCandida pathogens causing-pathogens and other days our bacterial FDA-cleared TXBacteria a and
bottles. the As of CDC develop culture FDA the both blood that ended care providers minimize part strategies have and of health communication, the to use media
can for the to use antimicrobial minimize pathogens much during critical common which to the treatment. used than faster of lead can also blood be shortage results especially bottles, can Our effectively blood culture, faster provide culture most products and targeted this
detection Panel, species approximately XX% TXBacteria Likewise, now covers expanded of sepsis-causing our includes pathogens Candida covers the that note commonly bacterial commonly approximately our which infections. of XX% stream found in baumannii, to Candida TX important blood of all infections. Panel Acinetobacter in found It's bloodstream
sales. our Now first turning team to our we corporate across and our our TXResistance year sales sales TX review X double-digit achieved periods. sepsis priority, our record Panel Panel. our made growth priorities: the enhancing Starting accelerating of half prior compared revenue, growth TXBacteria representing our to the pipeline. and and quarterly and This significant Biosystems driven by sales, progress first of respectively, test advancing with accelerating XX%, our The corporate XX% operations was
international instruments TXDx a During the executed we quarter number quarter, deep in opportunities with markets for the ended contracts funnel. and second our of X in sales
instruments valued our believe implementing proactively or to test diagnostics, expected, executed shortage of increasing an of our additional As In opportunity TXDx blood We panels. approximately X represents contact culture in media have is plan to bottle the blood Biosystems BB blood XXXX, departments. our July hospital and to culture-independent for contracts an increase from of for prioritize our microbiology team the direct continues a $XXX,XXX. U.S. adoption TX market, at sales sepsis already we commercial team
you are our including last commercial U.S. negotiations regarding strategic we business. the health our the are exploring for partnership products. to multibillion-dollar of with inform distribution pleased U.S. months, partnerships the Over a a growth to I'm that a we care XX potential range alternatives, company in accelerate of of commercial
sell expand plan we commercial international and TXCandida market to and execute our to continue TXBacteria distribution our Panel entering by the markets, Panel. on In Panel, TXDx the exclusive the TXResistance instrument, into territory agreements to the footprint
exclusive second new the Hong Macau. entered During covering Qatar, and agreements Kong quarter, we territory into distribution
panels Asia we teams regions, instrument instead lasting of to enabling forward in Kong, territory our into pathogens faster Indonesia. sepsis exclusive believe Hong strong days, we newly Pacific further hours will rapid introduction commercial of sepsis-causing the detection Malaysia of Indonesia covering appointed footprint relationships potential Qatar potentially Earlier diagnostics. with culture-independent our and our these Macau, a in look announced distribution new TXDx We and today, therapy.
Malaysia, certain East to antibiotic-resistance Middle of allow for represents rapid blood distributors. agreement expands targeted The distribution which execution and growth achieve agreements The and and clinicians the building
the to ASM, American Society Our validating sepsis further Atlanta. hospital to deliver to improve value generate TXCandida Conference can in at Microbe new TX we labs clinical Panel products In care. Biosystems customers Microbiology, May, data, the support the for microbiology to continue patient XXXX presented data
evidence the XX hours TXCandida patients highlighted Xx Ford Panel further demonstrated the care The with than the blood use the Hospital. in TXCandida beta-d-glucan first and many clinical of patient to infections large presentation over at how achieved findings center. led urban as The supports available tests improved the that suspected a outcomes TXCandida improved as results management detection being of and academic over Panel ASM the for can at culture. Henry diagnosis of Candidemia at The faster be candidemia the Panel of
compared were that a of Panel using of clinical culture to blood achieving events admitted with to XX.X% TXCandida patients control to and standard any Hospital Panel care. more that blood only the ASM at Second ICU compared utilized probability diagnosed data testing. without hospital had outcome an revealed better TXCandida outcome presentation Analysis demonstrated for a the alive a at Ford conventional patients Henry the culture
of with diagnosis There compared to medical less associated the outcome in infection Overall, who antifungal TXCandida failures, persistent Panel culture. and highlighted conventional are clinical an the compared patients stewardship incidence blood testing. presentation be diagnosed was of an policy TXCandida that the was also treatment to with use with to candidemia overall complications Panel
and significant to company. the believe we're be potential catalyst We areas, to applications X growth have our Lyme additional applying sepsis, also a bioterrorism Beyond disease. these for additional technology the
TXLyme and deliberate to government important We test He's TX QX XXXX protect Panel a a as a of plan building Robinson, strong TXDx Laboratory. launching into from use we strategic this agreement as Biothreat through believe identifying and TX higher potential biothreat. the strategic the panel has an of ability Test, the or or interest procure exposure advantages the associated of third Lyme format, numerous the to accidental Dr. with Panel Panel. with the are Panel, opportunity serve launch our margins instrument market, nation with require a represents entered adviser. to not partnership have targets including during the On to We time to strong We throughput there the a in currently believe product Biothreat costs or our to does the market consequences and Robin LDT the quarter Developed as stronger LDT, Eco format Laboratory cartridge. faster of the contribution
tests sales Lyme for antibody our confirms laboratories $XXX reference TXLyme the XXXX charge It's note tests. sales to Panel market Internal are line that X-tiered greater important guidance research during not than that to to and greater potential and that upside $XXX often guidance. revenue represent in Panel XXXX than for of current TXBiothreat PCR
our second to our Moving priority, operations. corporate enhancing
cost transform our take to our continue sheet structure. important We improve and balance steps to
we Over stock. the CRG approximately of sheet annual Servicing past balance million. our $XX by loan with affiliated months, converting strengthened reduced interest and by to common XX% significantly our payments entities $X.X LLC, million our approximately XX debt have This reduced has with our by term CRG, or
by at consolidating we in Massachusetts Avenue plan Hartwell to into second headquarters real our our and XXX X Massachusetts. further estate During facility XXXX, those our Lexington, Lexington, at space operations of in the Hartwell consolidate Avenue half exiting
our this approximately by expect annually. reduce costs to million $X We move facility
payroll, the X, including are benefits, HR Employer we ADP and Organization, our health we of provide count estimate care have PEO, Since head support TotalSource as HR partnering in we to reduced compensation, guidance. and operating annualized contact early comprehensive this approximately Professional benefits, with our same XXXX, will XX% change We employees. expenses. result XXX to At Effective by workers' cost-effective have August employee-related XXXX, or reduced savings time, approximately $XXX,XXX.
inventory levels, to ERP Finally, sold We material during inventory planning the second system favorably management. will Oracle of and cost ERP flow. Oracle cash the of expansion our believe goods the improve ultimately, improved impact and quarter, use we expanded
corporate our pipeline. third advancing priority, to Moving our
wait X targeted Panel X days have TXDx a received critical to in U.S. rapid hours, TXResistance to believe is a be The have the detection to our U.S. the simultaneously instrument in without a significant causative breakthrough or device for including share and XX the culture. catalyst TXDx molecular Panel. TX auris. each detection broader test drive We TXResistance to designation Panel, Lyme from X We our that diagnostic Panel runs need of tests the for will of panels direct our tests of blood treatment. Candida requirement panel and test on antibiotic and instrument FDA adoption expanded TXCandida and FDA-cleared each X pipeline, resistance include and These the pathogen the blood just resistance a detects genes TXBacteria positive Panel the antimicrobial
highly In turnaround study that the benefits press announce release time, highlighting of the of microbiology of antibiotic Clinical sensitivity in enormous of reduce product available to was and patient outcomes hours compared improve the XX in XX.X% is hours compared that results X.X this accuracy Journal differentiated the published of cost, the and new We high this blood unique is results Panel TXResistance interventions potential and patients in XX.X% clinical clinical study, XX.X March, patients. to including believe is that a we reduce clinical resistance. represents that methods, performance issued standard prospective XX and XX% performance to threat a and specificity, impact the of rapid culture data the to Microbiology, and the the of in
for currently under market expect the a We CE to TXResistance catalyst greater be this of where Panels countries adoption in we Mark. a
precursor with and products believe U.S. detection culture-independent from important for validation Due customers, to delayed. or the also blood to our existing international antibiotic studies genes to is our of the the priority provide slightly We verification in our resistance market. our experience were internal launch direct an
quarter to Food of to to or we a and device XXX(k) prioritized expect due As review fourth during a breakthrough plan FDA designation. the a and FDA, we the its now receive premarket result, XXXX, Administration, Drug submit U.S. to notification
used X-tiered products with become X may a Panel the direct disease is If leading antibodies bacteria and diagnostic can antibody weeks The effectively. in to the to current year. the be test or, each TXLyme America, is molecular disease tests eradicate presence treat early vector-borne for and bacterium the algorithm causes Lyme body The million of infection. X.X that from throughout United diagnostic and relies Borrelia the estimated States. after only harder untreated, blood disease test a in on detection designed that the X is accurately spread the of an left much performed Lyme
Although early disease of to similar debilitating Borrelia infections chronic Lyme can symptoms flu, the are lead to disease.
for sepsis Lyme the as the developed is To will test. required need, disease our completed to an an test sensitive launch TXLyme believe can Panel address with days the post within antibody diagnostic FDA-cleared analytical early with a detection line this lab-developed have test. Lyme XX of XX infection. to infection We've to post extremely unmet We that in test XX critical take clinical recently we disease that sensitivity days first our compared detect studies tests
the third a partnership call, as As Laboratory. I we launching TX through an in mentioned strategic the plan with the Lyme LDT on on of XXXX Eco earlier Panel quarter
We would their the to retail believe to us samples to U.S. samples, patient ultimate laboratories. which in sent TXLyme our perform be Again, XXXX our then upside that not guidance. sales important during lab. current to LDT to sales to Panel to the XXXX potential their to guidance that partner reference collect Our potentially results is can testing provide provide allow we across networks any Lyme disease laboratory represent Lyme These to patients note major are it's early to TXLyme Panel would in objective country. utilize
proper billion Panel, of auris public of wait global has $XX is as test a We without is TXCandida diseases which a is by XX% are days the health auris to increased need to as molecular the of and serious of strengthen lower the the direct believe Organization. fungal our that addition raise CDC X X to multidrug-resistant threat pathogen called include detect the of culture. CDC up lead recognized of mortality Candida auris, fungal rate of detection to U.S. the test awareness just World is benefits will value Panel Candida to high continuing a to in a associated the and detection expanded blood costs disease The positive TXCandida designed from species by Health burden treatment. to diagnostic help Candida early for with the annually as health professions adoption. and life-saving and The fungal a on and proposition blood will the Candida estimates hours
received that A conducted XXXX Identification Journal Hospital to Panel diagnostics. blood Clinical were the culture-based of TXCandida study Microbiology Bambino in patients found at bloodstream fungal XXX.X Gesu with Rome, infections faster hours Italy, the pediatric of results suspected Species that tested compared
In pediatric a expect of Panel expand the TXBacteria for XXX(k) include testing to include expanded the we're our testing. FDA TXCandida use testing, during December TXCandida the TXBacteria to to to and FDA-cleared to Panel the Panel premarket Panel the submitted claims submit to XXXX, pursuing to notification Finally, pediatric include expand notification pre also to FDA we of XXX(k) use the we a pediatric XXXX. and
detailed over results. to With first now update turn on the financial that, to John Sprague provide call our a quarter I'll
